play_arrow

keyboard_arrow_right

Listeners:

Top listeners:

skip_previous skip_next
00:00 00:00
playlist_play chevron_left
volume_up
Go to album
  • cover play_arrow

    LISTEN NOW: JafriQ Radio Live On Jafriq Radio

Africa

Africa’s Researchers Playing Crucial Role in Advancing HIV Prevention #HIVR4P2024

todayOctober 8, 2024 1

Background
share close

[ad_1]

Lima, Peru — Africa is contributing to groundbreaking data from the PURPOSE 2 study, which explores twice-yearly lenacapavir for HIV prevention. This study, with participants from South Africa and Uganda , is one of the scientific highlights showcased at the 5th HIV Research for Prevention Conference, better known as HIVR4P 2024, in Lima, Peru.

A key development is the promising results from the PURPOSE 1 study, which demonstrated that lenacapavir, a biannual HIV prevention injectable, reduced HIV acquisitions by 100% in cisgender women in Africa.

This study complements the PURPOSE 2 trial, which showed a 96% reduction in HIV acquisitions among trial participants .

“These findings confirm that lenacapavir for PrEP has the potential to transform the global HIV prevention landscape for people of all genders,” said Beatriz Grinsztejn, the President of the International AIDS Society (IAS), a nd also a member of the PURPOSE 2 study team, and an HIVR4P 2024 Organising Committee member.

Lenacapavir’s potential as a twice-yearly preventive option opens up new doors for HIV prevention in resource-limited settings. The convenience and reduced stigma associated with long-acting methods may lead to better adherence and outcomes, especially for women who often face challenges with daily PrEP use.

In addition to lenacapavir, African women are at the forefront of another exciting advancement—the three-month dapivirine vaginal ring. The monthly version of this ring, which was the world’s first woman-controlled HIV prevention product, is already approved in 11 African countries. Now, new data from South Africa suggests that the three-month version is even more promising, with lower costs and improved convenience.

The dapivirine vaginal ring (DVR) is flexible silicone ring that is inserted in the vagina and slowly releases an antiretroviral (ARV) drug called dapivirine, according to AVAC – an international non-profit organisation that is a key player in the global fight against HIV.

“It’s becoming increasingly clear that the HIV prevention field is focusing on expanding choice for women and on long-acting prevention technologies. And, in fact, the dapiverine vaginal ring was the 1st long-acting prevention technology to receive a positive regulatory assessment,” said Jeremy Nuttall, of the Population Council Center for Biomedical Research.

“The 3-month ring offers important benefits over the one-month ring. It’s only 4 rings a year rather than 12, which is a two-thirds reduction in the number of rings and packaging materials required per year. The estimated cost is not more than U.S.$16, excluding distribution costs, and that represents a 60% reduction in cost per year compared to the one-month ring,” said Nuttall.